Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:18 PM
Ignite Modification Date:
2025-12-24 @ 4:18 PM
NCT ID:
NCT00605566
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically confirmed neuroendocrine tumors
* Progressive and measurable metastatic disease
* Patients must not have disease that is currently amenable to surgery
* Life expectancy of greater than 3 months
* ECOG performance status ≤2
* Patients must have normal organ and marrow function
* Negative pregnancy test; agreement to use adequate birth control
Exclusion Criteria:
* Patients receiving chemotherapy or radiotherapy within last 4 weeks
* Patients that had received Sorafenib for advanced NET(neuroendocrine tumors) are not allowed
* Any other investigational agents within 4 weeks of study
* Patients with known brain metastases
* History of allergic reactions to compounds of similar chemical/biologic composition to sorafenib or cyclophosphamide
* Concurrent cancer from another primary site requiring treatment within the past 3 years
* Uncontrolled intercurrent illness
* Pregnant women and women who are breastfeeding
* HIV-positive patients receiving combination anti-retroviral therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00605566
Study Brief:
Protocol Section:
NCT00605566